 |
|
Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
March 28, 2008The Cystic Fibrosis Foundation announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.
Patients who took the drug for 14 days showed significant improvements in several key indicators of cystic fibrosis, including lung function, nasal potential difference measurements and sweat chloride levels. The findings suggest that VX-770 improves function of what is known as the faulty CFTR protein. This early data is promising and could have important implications for studies of other drugs in development.
This is the first time that any potential therapy has improved the abnormal sweat chloride (salt) levels in a person with CF. Excessive sweat chloride is a key clinical indicator of cystic fibrosis. The "sweat test" is the traditional diagnostic test for CF.
"These early results are an extraordinary endorsement of our hypothesis-that small molecules can correct the basic defect and affect the clinical indicators of cystic fibrosis," said Robert J. Beall, Ph.D., president and CEO of the Foundation. "The emerging data for VX-770 represents the most exciting results we've seen from a Phase 2 trial and increase our confidence that we're on the right track."
The compound VX-770 resulted from a collaboration between the Foundation and Vertex. In 1998, the Foundation approached Aurora Biosciences (acquired by Vertex in 2001) and made an initial investment to use cutting-edge technology-known as high throughput screening-to find compounds to attack the core defect in CF. Since that time, the Foundation has invested $79 million in the project, and the two organizations have closely collaborated to advance VX-770 and a second CF compound, known as VX-809, through research and into development.
"At a time when the model of venture philanthropy was wholly untested, the Cystic Fibrosis Foundation was willing to take a chance that Vertex's CF program would yield meaningful results for people with cystic fibrosis," said Joshua Boger, Ph.D., president and CEO of Vertex Pharmaceuticals. "The project carried significant risk that would have dissuaded many companies and investors from moving forward. Today, however, with the Foundation's financial, scientific and clinical network support, we have been able to bring two novel CF compounds into development and are encouraged by these early results for VX-770."
Overall, the Foundation has invested nearly $300 million in CF drug research with dozens of biotech collaborators nationwide. These collaborations with for-profit companies are part of the Foundation's unique venture philanthropy business model. The model, which is being emulated by other orphan disease organizations, has spawned a drug pipeline of more than 30 therapies in development.
Part One of the Phase 2a trial of VX-770 studied 20 cystic fibrosis patients over a 14-day period. Part Two of the study is expected to begin in the second quarter of 2008. Additional studies will evaluate the longer-term safety and efficacy of the compound.
Cystic fibrosis is a life-threatening genetic disease that affects about 30,000 people in the United States and 70,000 worldwide. CF is caused by a genetic mutation that results in a malfunctioning (or missing) protein that results in an imbalance of salt and water. This imbalance causes a cascade of mucus plugging, infection and inflammation in the lungs and other organs. The primary cause of death in CF is lung disease.
The predicted median age of survival for people with CF is age 37 - more than double what it was 25 years ago.
Cystic Fibrosis Foundation
"These early results are an extraordinary endorsement of our hypothesis-that small molecules can correct the basic defect and affect the clinical indicators of cystic fibrosis," said Robert J. Beall, Ph.D., president and CEO of the Foundation. "The emerging data for VX-770 represents the most exciting results we've seen from a Phase 2 trial and increase our confidence that we're on the right track."
The compound VX-770 resulted from a collaboration between the Foundation and Vertex. In 1998, the Foundation approached Aurora Biosciences (acquired by Vertex in 2001) and made an initial investment to use cutting-edge technology-known as high throughput screening-to find compounds to attack the core defect in CF. Since that time, the Foundation has invested $79 million in the project, and the two organizations have closely collaborated to advance VX-770 and a second CF compound, known as VX-809, through research and into development.
"At a time when the model of venture philanthropy was wholly untested, the Cystic Fibrosis Foundation was willing to take a chance that Vertex's CF program would yield meaningful results for people with cystic fibrosis," said Joshua Boger, Ph.D., president and CEO of Vertex Pharmaceuticals. "The project carried significant risk that would have dissuaded many companies and investors from moving forward. Today, however, with the Foundation's financial, scientific and clinical network support, we have been able to bring two novel CF compounds into development and are encouraged by these early results for VX-770."
Overall, the Foundation has invested nearly $300 million in CF drug research with dozens of biotech collaborators nationwide. These collaborations with for-profit companies are part of the Foundation's unique venture philanthropy business model. The model, which is being emulated by other orphan disease organizations, has spawned a drug pipeline of more than 30 therapies in development.
Part One of the Phase 2a trial of VX-770 studied 20 cystic fibrosis patients over a 14-day period. Part Two of the study is expected to begin in the second quarter of 2008. Additional studies will evaluate the longer-term safety and efficacy of the compound.
Cystic fibrosis is a life-threatening genetic disease that affects about 30,000 people in the United States and 70,000 worldwide. CF is caused by a genetic mutation that results in a malfunctioning (or missing) protein that results in an imbalance of salt and water. This imbalance causes a cascade of mucus plugging, infection and inflammation in the lungs and other organs. The primary cause of death in CF is lung disease.
The predicted median age of survival for people with CF is age 37 - more than double what it was 25 years ago.
Cystic Fibrosis Foundation
Cystic Fibrosis News and Current Cystic Fibrosis Events RSSClearing the airways in cystic fibrosis
By manipulating the machinery used by our cells for quality control, researchers from the University of Pittsburgh have found a way to restore the function of cystic fibrosis (CF) airway cells.
PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet
New phase 2 data published today in The Lancet show that the investigational oral drug PTC124 demonstrates activity in nonsense-mutation cystic fibrosis (CF). The data show that treatment with PTC124 results in statistically significant improvements in the chloride channel function of patients with nonsense-mutation CF. The study was conducted at the Hadassah Hebrew University Hospital in Jerusalem, Israel and sponsored by PTC Therapeutics (PTC).
Breaking the 'mucus barrier' with a new drug delivery system
Chemical engineers from Johns Hopkins University have broken the "mucus barrier," engineering the first drug-delivery particles capable of passing through human mucus - regarded by many as nearly impenetrable - and carrying medication that could treat a range of diseases. Those conditions include lung cancer, cervical cancer and cystic fibrosis, the research noted in a presentation scheduled for the 236th National Meeting of the American Chemical Society.
NIH scientists find a novel mechanism that controls the development of autoimmunity
Scientists at the National Institutes of Health (NIH) have found a mechanism in the immune systems of mice that can lead to the development of autoimmune disease when turned off.
Researchers discover cell's 'quality control' mechanism
Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells - sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science.
Most generalists reluctant to provide primary care for young adults with chronic illness
The majority of general internists and pediatricians in the United States are not comfortable serving as primary care providers for young adults with complex chronic illnesses that originate during childhood, according to findings from a new national survey.
Mucous breakthrough in mice holds promise for cystic fibrosis
A London, Canada scientist studying cystic fibrosis (CF) has successfully corrected the defect which causes the overproduction of intestinal mucous in mice.
Consortium develops new method to manipulate genetic material
A multi-institutional team of researchers, including scientists at the University of Minnesota Medical School, have developed a powerful tool for genomic research and medicine.
RNA emerges from DNA's shadow
RNA, the transporter of genetic information within the cell, has emerged from the shadow of DNA to become one of the hottest research areas of molecular biology, with implications for many diseases as well as understanding of evolution.
Should embryos with a hereditary disorder be transferred if no unaffected embryos are available?
The numbers of cycles of preimplantation genetic diagnosis or screening are rising steadily in Europe with over 2,700 reported in 2004 (the most recent year for which data are available).
More Cystic Fibrosis News Articles
 | Recipes for the Specific Carbohydrate Diet: The Grain-Free, Lactose-Free, Sugar-Free Solution to IBD, Celiac Disease, Autism, Cystic Fibrosis, and Other Health Conditions (Healthy Living Cookbooks) by Raman Prasad The Specific Carbohydrate Diet is a strict grain-free, lactose-free, and sucrose-free dietary regimen intended for those suffering from Crohn's disease and ulcerative colitis (both forms of IBD), celiac disease, IBS, cystic fibrosis, and autism. It is based on the work of Elaine Gottschall, who wrote Breaking the Vicious Cycle, which introduces the SCD and explains the importance of eliminating... |
 | The Troubled Dream of Genetic Medicine: Ethnicity and Innovation in Tay-Sachs, Cystic Fibrosis, and Sickle Cell Disease by Keith Wailoo, Stephen Pemberton Why do racial and ethnic controversies become attached, as they often do, to discussions of modern genetics? How do theories about genetic difference become entangled with political debates about cultural and group differences in America? Such issues are a conspicuous part of the histories of three hereditary diseases: Tay-Sachs, commonly identified with Jewish Americans; cystic fibrosis, often... |
 | The Power of Two: A Twin Triumph over Cystic Fibrosis by Isabel Stenzel Byrnes, Anabel Stenzel The tragedy of cystic fibrosis has been touchingly recounted before, but this is the first book to portray the symbiotic relationship between twins who share this life-threatening disease through adulthood. Isabel Stenzel Byrnes and Anabel Stenzel tell of their struggle to pursue normal lives while grappling with the realization that they might die young. Their story reflects the physical and... |
 | Sick Girl Speaks!: Lessons and Ponderings Along the Road to Acceptance by Tiffany Christensen Surprise! I’m still not dead! Okay, sure, I was born with an incurable genetic disease and, yes, I have faced terminal illness two times but … here I am! And I’m ready to speak! I’ve now been navigating the Western medical maze for over three decades. Along the way, I’ve had to learn some pretty painful lessons about how to advocate for myself and what happens if I don’t. I also know how scary... |
 | Parenting Children With Health Issues: Essential Tools, Tips, and Tactics for Raising Kids With Chronic Illness, Medical Conditions, and Special Healthcare Needs by Foster W. Cline, Lisa Greene 2008 Gold Winner of the Mom's Choice Awards, 2008 Winner of the Indie Excellence Awards for Parenting and Family, and 2007 Finalist for Foreword Magazine's Book of the Year! Special parenting skills are needed to raise kids with special needs. Whether your child struggles with allergies, asthma, diabetes, cystic fibrosis, an eating disorder or any other health issue, you will find the essential... |
 | As Long as We Both Shall Live: Two Novels by Lurlene Mcdaniel A change is coming, April Lancaster’s fortune cookie reads. Be prepared. But how could she be prepared for the news that she has an inoperable brain tumor? April’s life will never be the same. Then she meets handsome Mark Gianni. Mark has cystic fibrosis, but he also has a passion for life . . . and for April. When he asks April to marry him, she’s happier than she’s ever... |
 | Alex: The Life of a Child by Frank Deford Alexandra Deford, a precious and precocious girl, was just eight years old when she died in 1980 following a battle against the debilitating effects of cystic fibrosis, the number-one genetic killer of children. Her poignant and uplifting story touched the hearts of millions when it was first published and then made into a memorable television movie. A new introduction contains information... |
 | With Every Breath: stories by and about people living with cystic fibrosis Over 30,000 people in the US have cystic fibrosis, a life-threatening genetic disease that affects the lungs and digestive system. Physically, fighting it is a very perilous struggle. Emotionally, coping can oftentimes be even harder. With Every Breath consists of stories by and about people living with cystic fibrosis. Created to motivate, inspire, and generate positivity for those living... |
 | Taking Flight: Inspirational Stories of Lung Transplantation Lung Transplantation is still relatively new compared to other transplantation surgery. The first successful heart/lung transplant took place in 1981, with the first successful single lung transplant taking place in 1983. It was not until 1986 the first successful double lung transplant takes place. Even more recent is the living lobar transplant which the first successful one being in 1990. The... |
 | Forever Changes by Brendan Halpin 5:30 a.m., Brianna Pelletier gets ready for her daily pounding. As she lies on the couch, her dad beats her chest, then her back, coaxing the mucus out of her lungs. The pounding doesn’t take care of everything. Brianna’s held out for a long time, but a body with cystic fibrosis doesn’t last forever. It doesn’t matter that Brianna has a brilliant mathematical mind or that... |
| © 2008 BrightSurf.com |